Hepatitis B virus precore protein augments genetic immunizations of the truncated hepatitis C virus core in BALB/c mice

DNA immunization has been used to induce either humoral or cellular immune responses against many antigens, including hepatitis C virus (HCV). In addition, DNA immunizations can be enhanced or modulated at the nucleotide level. Genetic immunizations were examined in BALB/c mice through the use of plasmids and chimeric DNA constructs encoding HCV core proteins and hepatitis B virus (HBV) precore (preC) regions. Plasmids encoding the truncated HCV core induced potent humoral and cellular responses to HCV; pcDNA3.0A-C154 produced a stronger antibody response than pcDNA3.0A-C191 (P < 0.01) and pcDNA3.0A-C69 (P < 0.05). HBV preC enhanced the humoral and cellular immune responses of BALB/c mice to HCV; however, pcDNA3.0A-C69preC resulted in a weak cytotoxic T lymphocyte (CTL) response. In addition, the humoral and cellular immune responses to HCV of groups immunized with pcDNA3.0A-C154preC and pcDNA3.0A-C191preC plasmids were higher than those of groups immunized with pcDNA3.0A-C154 and pcDNA3.0A-C191. In vivo CTL responses verified that mice immunized with preC core fused DNAs showed significantly high specific lysis compared with mice immunized with HCV cores only (P < 0.01). In our study, pcDNA3.0A-C154preC led to the highest immune response among all DNA constructs. Conclusion: DNA that encodes truncated HCV core proteins may lead to increased immune responses in vivo, and these responses may be enhanced by HBV preC.     

Profiling of differentially expressed chemotactic-related genes in MCP-1 treated macrophage cell line using human cDNA arrays

AIM: To study the global gene expression of chemotactic genes in macrophage line U937 treated with human monocyte chemoattractant protein-1 (MCP-1) through the use of ExpreeChipTMO2 cDNA array. METHODS: Total RNA was extracted from MCP-1 treated macrophage line U937 and normal U937 cells, reversely transcribed to cDNA, and then screened in parallel with HO2 human cDNA array chip. The scanned result was additionally validated using RT-PCR. RESULTS: The result of cDNA array showed that one chemotactic-related gene was up-regulated more than two-fold (RANTES) and seven chemotactic-related genes were down-regulated more than two-fold (CCR1, CCR5, ccll6, GROβ, GROγ,IL-8 and granulocyte chemotactic protein 2) in MCP-1 treated U937 cells at mRNA level. RT-PCR analysis of four of these differentially expressed genes gave results consistent with cDNA array findings. CONCLUSION: MCP-1 could influence some chemokine and receptor expressions in macrophages in vitro. MCP-1 mainly down-regulates the expression of chemotactic genes influencing neutrophilic granulocyte expression (GROβ, GROγ, IL-8 and granulocyte chemotactic protein 2), and the mRNA level of CCR5, which plays a critical role in many disorders and illnesses.     

乳腺导管原位癌伴微浸润与导管原位癌的临床病理及X线表现对比分析

目的对比分析乳腺导管原位癌伴微浸润(DCISM)与导管原位癌(DCIS)的X线及临床病理表现及DCISM的预测因子。方法收集2016年1月至2020年7月在青岛大学附属医院经手术病理证实的DCISM及DCIS患者626例,患者术前均接受乳腺X摄影检查。参照乳腺影像报告和数据系统(BI-RADS)标准对DCISM与DCIS患者X线表现进行分类诊断。采用χ²检验或Fisher确切概率法分析DCISM与DCIS患者临床病理及X线表现的差异性,应用单因素和多因素二元logistic回归分析探讨与DCISM相关的危险因素。结果626例患者中,DCISM患者171例,DCIS患者455例。单因素回归分析表明,肿瘤直径≥2.7cm、高核级别、粉刺性坏死、淋巴结阳性、Ki67高表达、雌激素受体及孕激素受体阴性是DCISM的预测因子(P<0.05)。多因素回归分析显示,肿瘤直径≥2.7cm(OR 2.229,95%CI 1.505~3.301,P<0.001)、高核级别(OR 1.711,95%CI 1.018~2.875,P=0.043)、淋巴结阳性(OR 4.140,95%CI 1.342~12.773,P=0.013)是DCISM的独立预测因子(P<0.05)。乳腺X线摄影中,DCIS与DCISM患者的病变类型、有无钙化及钙化分布差异具有统计学意义(χ²分别为17.42、9.65、9.10,P<0.05),17.6%(80/455)的DCIS患者表现为隐匿性病变,49.1%(84/171)的DCISM表现为钙化伴肿块、非对称致密、结构扭曲。团簇状钙化多见于DCIS(41.5%,120/289),而区域性钙化在DCISM中更普遍(35.9%,47/131)。结论乳腺X线摄影表现为钙化性病变及区域性钙化在DCISM中更常见。肿瘤直径≥2.7cm、高核级别、淋巴结阳性是DCISM的独立预测因子。     

消化性溃疡病证关系探讨

本文通过对消化性溃疡病理因素、溃疡大小、部位，分期、有无活动性炎症等与溃疡病表现证型的关系探讨，以及证型与证微观定量指标的关系探讨，指出同一种溃疡病之所以表现为不同证型，关键可能在于内环境状态的差异，肝胃不和证、脾气虚证、肝郁脾虚证内环境状态的差别，或许是其不同临床表现的内在根源。     

中国脑型疟患者恶性疟原虫分离株裂殖子表面蛋白MSP1 第16- 17 区基因和MSP2 基因的分子克隆与鉴定

目的: 为设计研制安全有效的人脑型疟疫苗提供理论依据。方法: 根据MAD20 株裂殖子表面蛋白1 (MSP1) 和FC27 株裂殖子表面蛋白2 (MSP2) 基因编码区高度保守碱基设计并合成两对引物, 应用多聚酶链反应(PCR) 技术对5 例脑型疟患者恶性疟原虫云南省勐腊县勐罕分离株CMH/YN 和云南省盈江县农场CYJ/YN 分离株基因组DNA MSP1 第13- 17 区基因和MSP2 基因进行扩增, 并将扩增产物分别经EcoRI 和KpnI, BamHI 和HindIII 双酶切后, 分子定向克隆M13mp18 和M13mp19 载体, 转染大肠杆菌(E. coli) TG1, 从含X-gal 和IPTG 的LB平板上, 将随机筛选得到的单个无色噬菌斑经E. coli JM 103 扩增, 用碱裂解法抽提重组子复制型DNA (RFDNA ) 后, 再分别经EcoRI 和KpnI, BamHI 和HindIII 双酶切鉴定。结果: 证实重组子为编码脑型疟患者恶性疟原虫CMH/YN 和CYJ/YN 分离株MSP1 第16- 17 区基因和MSP2 基因分子克隆M13 载体。结论: 首次报道确证脑型疟患者恶性疟原虫CMH/YN 和CYJ/YN 分离株MSP1 第16- 17 区基因和MSP2 基因分别与MAD20 株MSP1 和FC27 株MSP2 相应基因完全一致。这些发现对研究预防人脑型疟疫苗和建立一种新型脑型疟恶性疟原虫检测方法具有重要意义。     

Clinical significance of the serum IgM and IgG to SARS‐CoV‐2 in coronavirus disease‐2019

ObjectiveTo explore the clinical value of serum IgM and IgG to SARS‐CoV‐2 in COVID‐19.Methods105 COVID‐19 patients were enrolled as the disease group. 197 non‐COVID‐19 patients served as the control group. Magnetic chemiluminescent immunoassay (MCLIA) was used to detect the IgM and IgG.ResultsThe peak of positive rates of SARS‐CoV‐2 IgM was about 1 week earlier than that of IgG. It reached to peak within 15–21 days and then began a slowly decline. The positive rates of IgG were increased with the disease course and reached the peak between 22 and 39 days. The differences in sensitivity of the three detection modes (IgM, IgG, and IgM + IgG) were statistically significant. The largest group of test cases (illness onset 15–21 days) showed that the positive rate of IgG was higher than IgM. Also, the sensitivity of IgM combined with IgG was higher than IgM or IgG. IgM and IgG were monitored dynamically for 16 patients with COVID‐19, the results showed that serological transformation of IgM was carried out simultaneously with IgG in seven patients, which was earlier than IgG in four patients and later than IgG in five patients.ConclusionThe detection of SARS‐CoV‐2 IgM and IgG is very important to determine the course of COVID‐19. Nucleic acid detection combined with serum antibody of SARS‐CoV‐2 may be the best laboratory indicator for the diagnosis of SARS‐CoV‐2 infection and the phrase and predication for prognosis of COVID‐19.     

创伤后感染致多器官功能障碍综合征患者血清β-hBD-2、OPN、pro-ADM和NPt水平的变化

目的：探讨多器官功能障碍综合征（multipleorgandysfunctionsyndrome,MODS）患者的炎症感染病理过程中炎性介质水平的变化。方法：血清人类B防御素-2（humanB．defensin-2,β—hBD-2）、骨桥蛋白（osteopontin,OPN）和新蝶呤（neoptefin,NPt）采用酶联免疫分析法（ELISA）测定,肾上腺髓质素前体（pro-adrenomeduUin,pro—ADM）检测采用化学免疫发光法。结果：四项血清标志物测定结果分别显示,对照组和确诊时组B-hBD-2、OPN、pro-ADM、NPt四种血清炎症介质标志水平均显著高于正常人组（P〈0．05,P〈0．01）,出院前组β-hBD-2、OPN水平显著高于正常人组,另两项指标均与正常人组比较无显著性差异（P均〉0．05）;同时确诊时组与对照组比较β—hBD-2、OPN、pro-ADM三项指标水平也显著升高（P〈0．05,P〈0．01）,NPt水平患者组呈略高,但无统计学意义（P〉0．05）;出院前组β-hBD-2、OPN、pro-ADM、NPt四种血清炎症介质标志水平均显著低于确诊时组（P〈0．05,P〈0．01）。结论：MODS患者的炎症感染病理过程中炎性介质水平显著升高,其测定对于临床抗感染治疗提供重要价值。     

Synthesis and Photovoltaic Performance of a [1,2,3]Triazolo[4,5‐g]quinoxaline‐Based Low‐Bandgap Polymer

A narrow‐bandgap conjugated polymer, PFDTBTzQ‐2OC1, is prepared by alternating [1,2,3]triazolo[4,5‐g]quinoxaline and 9,9‐didodecyl‐fluorene. With a bandgap of 1.63 eV, this polymer has wide absorption ranging from 300–760 nm in film. Bulk heterojunction solar cells fabricated by blending PFDTBTzQ‐2OC1 with [6,6]‐phenyl‐C₇₁‐butyric acid methyl ester exhibit a maximum power conversion efficiency of 1.31%, with a short‐circuit current density of 1.98 mA cm^–2, an open‐circuit voltage of 0.74 V, and a fill factor of 0.47.

     

Carbazole‐Substituted Triphenylamine and Diketopyrrolopyrrole Alternating Copolymer for Photovoltaic Cells

A new alternating conjugated polymer (PTCDPP) of carbazole‐substituted triarylamine and diketopyrrolopyrrole is prepared and characterized in detail. The polymer exhibits two strong absorption bands at 345 and 600 nm. With highest occupied molecular orbital (HOMO) and lowest unoccupied molecular orbital (LUMO) energy levels of ?5.13 eV and ?3.67 eV, PTCDPP displays an energy gap of 1.66 eV. PTCDPP‐based bulk heterojunction solar cells with a structure of fluorinated tin oxide (FTO)/TiO₂/PTCDPP:[6,6]‐phenyl‐C61‐butyric acid methyl ester (PCBM)/MoO₃/Ag are fabricated. The devices are optimized by adjusting the composition of the PTCDPP:PCBM active layer, thermal treatment, and addition of processing additives. The device based on PTCDPP:PCBM (1:4, w/w) shows a power conversion efficiency (PCE) of 2.31%, with a short‐circuit current of 4.17 mA cm^?2, an open‐circuit voltage of 0.79 V, and a fill factor of 0.35. The best cell performance (2.65% PCE) is achieved by using 1,8‐diiodooctane (3%, v/v) as a processing additive and annealing the active layer at 80 °C.